PI Healthsciences, a provider of specialty chemistry services, has acquired Archimica S.p.A. The new Archimica business portfolio will include CRO solutions, CDMO solutions, and KSM/API solutions.

“We are excited about this acquisition as it marks a solid and accelerated beginning of PI’s journey in the pharma space,” said Mayank Singhal, vice chairperson and managing director of PI Industries Ltd. “Our unique ability to build concrete offerings from abstract situations and leverage our capabilities across complex chemistries in the value chain will once again help create a differentiated value proposition for our stakeholders.”

Singhal explained that the acquisition aligns with PI’s approach of working with global innovators and being at the forefront of innovation, science, technology, and human ingenuity to create transformative solutions in life sciences with the purpose of reimagining a healthier planet.

“We are excited to welcome the talented team from Archimica to the PI family. We look forward to deploying all our combined expertise towards unique value delivery for our customers. I compliment PI’s leadership team and external advisors in fructifying this strategic opportunity,” said, Singhal.  

Peter Löw, founder and owner of Liva Group, said, “Our investment in Archimica SpA has been a great success story for all the stakeholders in the business. The sale of Archimica to the strategic buyer PI HealthSciences is the final piece in our strategy of fully utilizing Archimica’s potential. Like Archimica, PI HealthSciences is pursuing an ambitious growth strategy and is in a perfect position to support the company in its future development.”